Health Canada 2026-27 Plan Ties Generic Approvals to Reimbursement

Health Canada's 2026-27 Departmental Plan identifies "improving the accessibility, affordability, and timeliness of pharmaceuticals for Canadians" as one of the department's key priorities for the coming year, a framing that coincides with the first generic semaglutide authorizations in the G7 [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374].

Departmental plan priorities

According to the plan, Health Canada intends to fund Canada's Drug Agency to conduct health technology assessments, advance appropriate-use strategies for prescription drugs, and "bring new medications to Canadians faster" by aligning regulatory approvals and reimbursement recommendations [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374]. The department's plan states that it will work toward issuing regulatory approval of a drug and public-plan recommendations in closer coordination [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374].

Two generic semaglutides now authorized

The policy framing arrives as Health Canada authorized the first generic semaglutide injection on April 28, 2026, filed by Dr. Reddy's Laboratories as a generic version of Ozempic [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. On May 1, 2026, the department authorized a second generic semaglutide injection, this one filed by Canadian-based Apotex [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

Health Canada said it is reviewing seven other submissions for generic semaglutide from different companies and expects further regulatory decisions "in the coming weeks and months" [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. At the time of the first authorization, eight other submissions were under review [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html].

Generic cost expectations

Health Canada has stated that many generic medicines in Canada are 45% to 90% cheaper than their brand-name counterparts [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374]. The department has said that the availability of generic drugs "is expected to have a positive impact in Canada, including potential cost savings for patients and the healthcare system" [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html].

The authorized generic, like existing brand-name products, is indicated for the once-weekly treatment of adult patients with type 2 diabetes to manage blood sugar levels [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. Generic semaglutide products are described as pharmaceutically equivalent to the brand-name biologic drug [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

Employer benefits angle

HR Reporter framed the approval as a move that could lower costs for employer-sponsored drug plans that cover type 2 diabetes treatments commonly used by working-age Canadians [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374]. Dana Small, a neurology and neurosurgery professor at McGill University, told Global News that including generic GLP-1 drugs in insurance plans makes economic sense, citing reduced costs related to chronic disease prevention [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374].

Small also urged caution, noting that "the moment you stop taking it, everything goes back to the way it was" [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374].

Continued post-market monitoring

Health Canada said it will continue to monitor the safety and effectiveness of all generic semaglutide products and will take appropriate action should any unexpected safety or effectiveness concerns arise [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. The regulator added that its review ensures differences between the generic products and the reference biologic "do not affect the safety, efficacy, or quality of the drug" [Source: hrreporter.com/focus-areas/compensation-and-benefits/canada-first-in-g7-to-approve-generic-ozempic/394374].

Canadians tracking the cascade of pending decisions can follow our generic semaglutide tracker and review plan options through our insurance coverage checker. Additional background on brand products including Wegovy, Rybelsus, Mounjaro, and Zepbound is available, with general questions answered in our FAQ.

This article is for informational purposes only and does not constitute medical advice.